Updates are available Erratum dated 2017-09-01
Click to view Erratum: https://doi.org/10.1038/nrd.2017.173
-
Authors
Hutchings, Catherine J.
Koglin, Markus
Olson, William C.
Marshall, Fiona H.
- License Information
-
More Information
Article History
First Online: 14 July 2017
Change Date: 1 September 2017
Change Type: Correction
Change Details: In the article, the clinical trial for the biparatopic CXCR2 nanobody was described as being for cancer instead of inflammation. This error has been corrected in the online version.
Competing interests
: C.J.H. is a shareholder and owns stock options of Heptares Therapeutics and Sosei Group, and has provided consultancy services to Heptares Therapeutics, TetraGenetics, Crescendo Biologics, Abcam, Tusk Therapeutics and xCella Biosciences. M.K. and F.H.M. are employees, shareholders and hold stock options of Heptares Therapeutics and Sosei Group. W.C.O. is an employee, a shareholder and holds stock options of Regeneron Pharmaceuticals.
